Terrain Support — SASP Suppression

What this page covers

This page covers apigenin’s activity as a senomorphic agent — a compound that changes the behaviour of senescent cells without necessarily killing them outright.

That makes it distinct from the direct tumour-cell mechanisms covered elsewhere. It also connects directly to the tumour microenvironment.

What is the SASP and why does it matter in cancer?

Senescent cells have permanently stopped dividing, but they have not died. They secrete inflammatory cytokines, chemokines, growth factors, and proteases known as the senescence-associated secretory phenotype, or SASP.

In oncology, SASP matters for two main reasons:

1. Pro-tumourigenic signalling: SASP factors such as IL-6, IL-8/CXCL8, IL-1α/β, and TNF-α can stimulate neighbouring cancer cells, promote invasion, weaken immune surveillance, and drive treatment resistance.

2. Therapy-induced senescence: radiation, platinum drugs, anthracyclines, and other treatments can induce senescence in both cancer cells and stromal cells. Those cells may then secrete SASP and help surviving cancer cells recover.

For the broader senescence framework, see Senescence — The Second Escape Route.

Apigenin’s senomorphic mechanism

Apigenin reduces SASP output through several documented routes:

• blocking the interaction between ATM/p38 MAPK and HSPA8, which helps prevent transition from acute stress signalling into chronic pro-inflammatory SASP

• inhibiting NF-κB p65 activity through IRAK1/IκBα signalling, reducing SASP-related cytokine transcription

• directly binding PRDX6 and blocking its iPLA2 activity, an upstream regulator of inflammatory signalling

• suppressing IL-1α signalling through IRAK1, p38 MAPK, and NF-κB, reducing aggressive SASP behaviour in breast cancer stromal cells

In preclinical studies, apigenin reduced SASP expression in bleomycin-induced senescent fibroblasts, in aged-rat kidney tissue, and in breast tumour models. In irradiated animals, apigenin also improved physical function.

Connection to chemoresistance

A 2025 study showed that apigenin, used as a senomorphic agent, reduced the malignancy promoted by senescent stromal cells in co-culture with cancer cells and restrained chemoresistance when paired with chemotherapy.

That supports a specific rationale for apigenin during or after chemotherapy. The goal is not only to increase apoptosis in cancer cells, but also to reduce SASP-driven survival signals from treatment-damaged stromal cells.

What this is not

Apigenin’s senomorphic activity is not the same as classic senolytic activity.

Current evidence shows that apigenin reliably suppresses the SASP and reduces the malignant help that senescent stromal cells can provide. It does not yet show the same consistent, selective senescent-cell killing seen with more established senolytic compounds.

Within the Senolytic Pulse Protocol, apigenin is best understood as follow-up pressure on MCL-1 and residual BCL-2/BCL-xL escape pathways in stressed and senescence-like cells. Its more firmly evidenced role remains SASP modulation.

References

• Zhang B, et al. Repurposing the plant-derived compound apigenin for senomorphic effects on chemoresistance

• Zhang B, et al. Targeting Senescence with Apigenin Improves Chemotherapeutic Efficacy

• Dong Z, et al. Apigenin as a bioactive compound for longevity